UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 455

Sortiert nach

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer

Annals of oncology, 2017-02, Vol.28 (2), p.298-304

2017

Volltextzugriff (PDF)

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population

Annals of oncology, 2010-04, Vol.21 (4), p.692-706

2010

Volltextzugriff (PDF)

Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer

Annals of oncology, 2005-07, Vol.16 (7), p.1069-1075

2005

Volltextzugriff (PDF)

Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

Cancer treatment reviews, 2012-05, Vol.38 (3), p.173-184

2012

Volltextzugriff (PDF)

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

Annals of oncology, 2005-05, Vol.16 (5), p.780-785

2005

Volltextzugriff (PDF)

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.76 (3), p.410-415

2012

Volltextzugriff (PDF)

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Annals of oncology, 2010-03, Vol.21 (3), p.540-547

2010

Volltextzugriff (PDF)

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)

Annals of oncology, 2013-06, Vol.24 (6), p.1534-1542

2013

Volltextzugriff (PDF)

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2013-09, Vol.81 (3), p.416-421

2013

Volltextzugriff (PDF)

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2009-06, Vol.27 (18S), p.CRA8000-CRA8000

2009

Volltextzugriff (PDF)

Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies

Clinical pharmacology and therapeutics, 2009-11, Vol.86 (5), p.519-526

2009

Volltextzugriff (PDF)

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

The New England journal of medicine, 2019-02, Vol.380 (8), p.720-728

2019

Volltextzugriff (PDF)

Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3760-3767

2005

Volltextzugriff (PDF)

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

Annals of oncology, 2013-01, Vol.24 (1), p.90-96

2013

Volltextzugriff (PDF)

Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer

Annals of oncology, 2007-01, Vol.18 (1), p.110-115

2007

Volltextzugriff (PDF)

Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

Annals of oncology, 2000-06, Vol.11 (6), p.673-678

2000

Volltextzugriff (PDF)

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.676-684

1999

Volltextzugriff (PDF)

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Cancer, 2018-01, Vol.124 (2), p.271-277

2018

Volltextzugriff (PDF)

Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer

Chest, 2000-04, Vol.117 (4), p.144S-151S

Belani, Chandra P.

2000

Volltextzugriff (PDF)

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer

Annals of oncology, 2004-02, Vol.15 (2), p.247-251

2004

Volltextzugriff (PDF)

Single agents in the second-line treatment of non-small cell lung cancer

Seminars in oncology, 1998-06, Vol.25 (3 Suppl 8), p.10-14

Belani, C P

1998

Volltextzugriff (PDF)

Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer

Seminars in oncology, 2001-08, Vol.28 (4 Suppl 14), p.14-16

Belani, Chandra P

2001

Volltextzugriff (PDF)

Combined modality therapy for unresectable stage III non-small cell lung cancer: New chemotherapy combinations

Chest, 2000-04, Vol.117 (4), p.127S-132S

BELANI, C. P

2000

Volltextzugriff (PDF)

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma : Sequential phase II trials by the Cancer and Leukemia Group B

Cancer, 1999-11, Vol.86 (10), p.1985-1991

1999

Volltextzugriff (PDF)

1 – 25 von 455

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(434)
Mit Volltextzugriff
(394)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(209)
Humans
(200)
Life Sciences & Biomedicine
(200)
Oncology
(118)
Biological And Medical Sciences
(117)
Medical Sciences
(114)
Male
(104)
Female
(101)
Middle Aged
(88)
Lung Neoplasms - Drug Therapy
(85)
Aged
(81)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(76)
Adult
(66)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(64)
Pharmacology. Drug Treatments
(55)
Lung Neoplasms - Pathology
(53)
Antineoplastic Agents
(50)
Chemotherapy
(41)
Paclitaxel - Administration & Dosage
(41)
Treatment Outcome
(41)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(119)
Seminars In Oncology
(33)
Lung Cancer
(25)
Clinical Lung Cancer
(23)
Journal Of Thoracic Oncology
(14)
Annals Of Oncology
(12)
Anesthesiology
(11)
Anesthesia And Analgesia
(10)
Cancer
(10)
Cancer Chemotherapy And Pharmacology
(9)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer

EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population

Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer

Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)

Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer

Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab

A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer

Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC)

Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non–Small-Cell Lung Cancer

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non–Small-Cell Lung Cancer

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer

Single agents in the second-line treatment of non-small cell lung cancer

Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer

Combined modality therapy for unresectable stage III non-small cell lung cancer: New chemotherapy combinations

Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma : Sequential phase II trials by the Cancer and Leukemia Group B

Suchergebnisse filtern